Price$12.12-0.02 (-0.16%)
01:45 PM07:45 PM
News · 26 weeks35-75%
2025-10-262026-04-19
Mix2890d
- Insider17(61%)
- Earnings4(14%)
- SEC Filings3(11%)
- Other2(7%)
- Analyst1(4%)
- Leadership1(4%)
Latest news
25 items- PROrthofix to Report First Quarter 2026 Financial ResultsCompany to Host Conference Call on Tuesday, May 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7578740. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Informati
- INSIDERSEC Form 4 filed by Cedron Jorge Andres4 - Orthofix Medical Inc. (0000884624) (Issuer)
- SECOrthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Orthofix Medical Inc. (0000884624) (Filer)
- PROrthofix Realigns Spine Leadership to Strengthen Focus and ExecutionCompany Reports Preliminary First Quarter 2026 Net Sales and Reaffirms 2026 Outlook Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to accelerate profitable growth and sharpen execution across its commercial and innovation priorities. The Company also reported preliminary, unaudited net sales results for the first quarter ended March 31, 2026. Spine Leadership Realignment To accelerate decision-making, sharpen leadership accountability, and further advance commercialization of the 7D™ navigation platform, Orthofix has streamlined its Spine organization by eliminating the rol
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Orthofix Medical Inc.SCHEDULE 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
- INSIDERSEC Form 4 filed by Vitale Lucas4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERDirector Capps Vickie L bought $62,324 worth of shares (5,000 units at $12.46), increasing direct ownership by 22% to 27,585 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERCFO Andrews Julie sold $60,980 worth of shares (4,788 units at $12.74), decreasing direct ownership by 5% to 88,746 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERCP&BOO Vitale Lucas sold $29,445 worth of shares (2,312 units at $12.74), decreasing direct ownership by 1% to 164,718 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERPresident & CEO Calafiore Massimo sold $155,633 worth of shares (12,220 units at $12.74), decreasing direct ownership by 4% to 320,136 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERPresident, Global Limb Recon Fisher Patrick sold $19,562 worth of shares (1,536 units at $12.74), decreasing direct ownership by 3% to 50,633 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERPres, Global Ops & Qual Mcpherron Aviva sold $32,591 worth of shares (2,559 units at $12.74), decreasing direct ownership by 4% to 67,853 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERPresident, Global Spine Reinhardt Max sold $27,166 worth of shares (2,133 units at $12.74), decreasing direct ownership by 8% to 25,348 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERCLO Cedron Jorge Andres sold $35,342 worth of shares (2,775 units at $12.74), decreasing direct ownership by 4% to 62,749 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERPresident & CEO Calafiore Massimo was granted 115,119 shares, increasing direct ownership by 53% to 332,356 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERPres, Global Ops & Qual Mcpherron Aviva was granted 23,024 shares, increasing direct ownership by 49% to 70,412 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERCFO Andrews Julie was granted 35,495 shares, increasing direct ownership by 61% to 93,534 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERCLO Cedron Jorge Andres was granted 23,024 shares, increasing direct ownership by 54% to 65,524 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERCP&BOO Vitale Lucas was granted 19,186 shares, increasing direct ownership by 13% to 167,030 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERPresident, Global Limb Recon Fisher Patrick was granted 21,105 shares, increasing direct ownership by 68% to 52,169 units (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- INSIDERLarge owner Engine Capital Management, Lp bought $1,734,956 worth of shares (137,858 units at $12.59) (SEC Form 4)4 - Orthofix Medical Inc. (0000884624) (Issuer)
- SECSEC Form 10-K filed by Orthofix Medical Inc.10-K - Orthofix Medical Inc. (0000884624) (Filer)
- SECOrthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Orthofix Medical Inc. (0000884624) (Filer)
- PROrthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial GuidanceOrthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2025, provided full-year 2026 financial guidance and updated its three-year financial targets. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Fourth quarter reported 2025 net sales of $219.9 million, including sales from M6 artificial cervical and lumbar discs, and non-GAAP pro forma net sales of $218.6 million, excluding sales from M6 discs, representing an increase of 2% on a reported basis and 3% on a non-GAAP pr
- PROrthofix to Participate in Upcoming Investor ConferencesOrthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Canaccord Genuity 2026 Musculoskeletal Conference - New Orleans, March 2, 2026, 9:30 am CT TD Cowen 46th Annual Health Care Conference - Boston, March 3, 2026, 11:10 am ET Interested parties can access the live and archived webcast of the presentations in the "Events & Presentations" section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix regularly shares important u